| Assessment Status | Rapid Review Complete |
| HTA ID | 25048 |
| Drug | Givinostat |
| Brand | Duvyzat® |
| Indication | Givinostat (Duvyzat®) for the treatment of Duchenne muscular dystrophy (DMD) in ambulant patients, aged 6 years and older, and with concomitant corticosteroid treatment. |
| Assessment Process | |
| Rapid review commissioned | 05/08/2025 |
| Rapid review completed | 14/08/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of givinostat compared with the current standard of care. |